Smith & Nephew (LON:SN) Insider Deepak Nath Sells 1,240 Shares

Smith & Nephew plc (LON:SN) insider Deepak Nath sold 1,240 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total transaction of £15,586.80.

Deepak Nath also recently made the following trade(s):

• On Monday, August 18th, Deepak Nath sold 18,007 shares of Smith & Nephew stock. The stock was sold at an average price of GBX 1,351, for a total transaction of £243,274.57.

Smith & Nephew Trading Down 0.4%

Shares of LON:SN traded down GBX 4.50 during trading on Wednesday, hitting GBX 1,266.50. 2,002,694 shares of the stock were exchanged, compared to its average volume of 343,671. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The company has a market capitalization of £13.88 billion, a P/E ratio of 45.60, a PEG ratio of 0.46 and a beta of 0.62. The company has a 50-day simple moving average of GBX 1,360.71 and a two-hundred day simple moving average of GBX 1,227.13.

Analysts Set New Price Targets

A number of research firms have issued reports on SN. Berenberg Bank upped their target price on shares of Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the company a “hold” rating in a report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the company a “hold” rating in a research report on Wednesday, August 6th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th. Citigroup boosted their price target on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Royal Bank Of Canada increased their price target on Smith & Nephew from GBX 1,400 to GBX 1,700 and gave the stock an “outperform” rating in a research note on Monday, October 20th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of GBX 1,487.60.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.